Who We Are

We are a healthcare capital markets team comprised of ex publicly traded C level executives, healthcare institutional equity sales, and sell-side research analysts at bulge bracket and boutique Healthcare investment banks. We specialize in micro-cap, small-cap, and mid-cap Healthcare.

Josh Berg
Founder, Managing Partner

Mr. Josh Berg is an experienced healthcare investment professional with over 20 years of institutional capital markets, investor relations, investment banking, and equity investment management expertise. Mr. Berg is well-versed and skilled at identifying value at all stages of a corporate life cycle and specializes in strategically building institutional shareholder bases for multinational healthcare organizations. Mr. Berg’s healthcare institutional investor relationships collectively manage more than $300 billion in equity value.

Prior to founding Berg Capital Markets, LLC, Mr. Berg developed expertise in institutional equities with bulge bracket and boutique healthcare centric investment banks including Leerink Partners, Wells Fargo Securities, and Pacific Growth Equities. Previous to Mr. Berg’s 11 years of investment banking experience, he facilitated the raise of over $2.0 billion in equity securities for Jurika & Voyles, LP, a value-based institutional equity investment management firm based in Oakland, California.

Through Berg Capital Markets, Mr. Berg and his colleagues successfully deliver a robust, full-service capital markets solution for both public and private healthcare companies.

Mr. Berg graduated with a Bachelor of Arts degree in Economics from the University of California at Santa Cruz. Mr. Berg currently lives in San Diego, California, and enjoys reading, running, traveling, working, cooking, working out, investing, and spending time with his children. 
See investor testimonials

 


 

Aaron Gorin
Senior Analyst

Mr. Aaron Gorin is an experienced healthcare investment professional with over 12 years of experience in strategic, financial, and operational analysis of public and private Healthcare companies. Mr. Gorin specializes in conducting due diligence, valuation analysis, market research, and strategic competitive analysis for biotechnology, pharmaceutical, and medical device companies.

Prior to joining Berg Capital Markets, LLC, Mr. Gorin was a Healthcare Equity Research Analyst at Morgan Stanley and Bank of America/Merrill Lynch where he focused on Biotech, Life Science Tools, Diagnostics, and Healthcare Services companies, including both domestic and international equities, as well as cap ranges from $50m-$50b. During his tenure, Mr. Gorin was instrumental in initiation of coverage reports on several high profile IPOs, and was involved in analysis of highly complex situations including poison pill takeovers, contentious proxy battles, leveraged buyouts, and activist campaigns. Prior to that, Mr. Gorin was a management consultant and a venture capitalist focusing on Life Science Investments at a privately held firm in New York. In this capacity, Mr. Gorin screened and triaged hundreds of potential deal targets including both compound-related and company-related transactions for acquisition as part of a Venture Fund, and worked on projects presenting to C-level management at Top 10 Global Pharmaceutical companies.

Mr. Gorin graduated from Cornell University with an Masters in Health Economics and Administration and a Bachelors in Economics.  Mr. Gorin currently lives in New York City with his wife and five children and in his free time enjoys reading, chess, tennis, and volunteering for various non-profit and religious organizations.



Dirk van den Boom, Ph.D.

Senior Advisor

Dr. van den Boom is an advisor to Berg Capital Markets on the Genomic Technologies and Molecular Diagnostics industry.
 
Dr. van den Boom most recently served as President, CEO and Member of the Board of Directors of Sequenom, Inc. until its acquisition by LabCorp, Inc. He previously held the position of Chief Scientific and Strategy Officer overseeing Sequenom’s research and development, strategic planning and business development activities.
 
Dr. van den Boom has co-authored over 90 peer-reviewed publications and is an inventor on over 50 patents and patent applications.
 
Dr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry.

 


 

Dean HolterDaniel S. Grosu, MD, MBADaniel S. Grosu, MD, MBA
Senior Medical Advisor


Dr. Grosu is the Founder and Managing Partner of GENOPRAXIS, LLC, a San Diego based specialty consulting firm dedicated to enabling the practical implementation of genomic testing technologies. He is an advisor to Berg Capital Markets on the Molecular Diagnostics industry.
 
Dr. Grosu most recently served as Chief Medical Officer at Sequenom, Inc. until its acquisition by LabCorp, Inc. Previously, he was at Illumina, Inc., where he served as the Company’s first Chief Medical Officer. He established the Medical Affairs and Clinical Development functions at Illumina, and led the team that performed the clinical studies for the first FDA-cleared and CE-marked next-generation sequencing (NGS) IVD platform and IVD assays.

Earlier in his career, Dr. Grosu held positions of increasing responsibility in the Diagnostics space at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. He holds an MD (with Distinction in Research) from Saint Louis University School of Medicine (Missouri, USA) and an MBA from the University of Oxford (United Kingdom).


 

Dean HolterNisha Hirani, M.D.
Chief Scientific Advisor

 

Nisha Hirani, M.D. is an experienced healthcare professional who serves as the Chief Scientific Advisor for Berg Capital Markets, LLC. Dr. Nisha Hirani has over 8 years of experience as a healthcare consultant preparing proprietary client focused services including due diligence, valuation analysis, market research, and product research for biotechnology, pharmaceutical, and medical device companies as well as institutional investors. Dr. Hirani is also a contributing writer for platforms such as Seeking Alpha and StockViews.

 

Previously, Dr. Hirani worked as a biotechnology research analyst producing institutional quality equity research for under-valued and under-followed healthcare, biotechnology and medical device companies. Dr. Hirani’s initiating coverage reports, research reports and articles have been featured on both institutional and retail platforms including Thomson Reuters First Call, Bloomberg, Wall Street Source, Yahoo! Finance, Fidelity.com, and Google Finance. In the past, Dr. Hirani has taught embryology, performed research in the area of optical mammography, and taught English as a Second Language (ESL) classes.

 

Dr. Hirani graduated from Tufts University with a B.S. in Biomedical Engineering and B.S in Biology, and received her Doctor of Medicine (M.D.) degree from St. George’s University School of Medicine. She completed her clinical clerkships primarily through the Barnabas Health System located in the New York Metropolitan area. In her free time, Dr. Hirani enjoys tennis, canvas painting, volunteering for various non-profit organizations, and spending time with her family.


 

Dean Holter

Michael Rodriguez
Advisor

 

Mr. Rodriguez is a financial advisor to Berg Capital Markets having served in a variety of financial and operating roles in diagnostics, life sciences, medical devices, and healthcare services.


Mr. Rodriguez most recently served as Chief Financial Officer of Epic Sciences, Inc., an early-stage, venture-backed life sciences startup. He previously held the positions of Chief Operating Officer and Chief Financial Officer of Clarient, Inc., prior to and after its acquisition by GE Healthcare.


Mr. Rodriguez has developed and led robust financial, investor relations, and operations organizations in public and private companies, having raised capital and overseen numerous buy-side and sell-side M&A transactions in both settings.


He earned his Master’s in Business Administration from Stanford University, and his Bachelor’s in Accounting from the University of Southern California.


 

Dean HolterDean Holter, Esq.
General Counsel and Chief Financial Officer

 

Dean Holter is an attorney, serving as both General Counsel and Controller to Berg Capital Markets, LLC. Mr. Holter has many years experience serving businesses as both General Counsel and Chief Financial Officer or Controller. Prior to joining Berg Capital Markets, LLC, Mr. Holter served as General Counsel and CFO to Christensen Global Strategies, an international consulting firm whose clients include United Nations Foundation, Clinton Global Initiative, Duke Energy, FEMSA, and Microsoft, among other Fortune 500 companies. While at Christensen Global Strategies, Mr. Holter also served as the project lead in the successful purchase of several commercial scale solar projects in California and Oregon, contracting with Renewable Technology Development, one of the largest solar thermal developers in California, and Chromasun, a leader in solar thermal technology. Prior to Christensen Global Strategies, Dean served as the General Counsel and General Manager of Idaho Capital, a private collateralized real estate lending group.



Sierra
Kelly Spoon

Executive Personal Assistant

Ms. Kelly Spoon is Executive Assistant to Josh Berg, CEO, Managing Partner, Berg Capital Markets, LLC. Ms. Spoon has more than 20 years of C-Level professional and executive assistance experience. Ms. Spoon also assists the analytical team at Berg Capital Markets in multiple administrative capacities. Ms. Spoon is a valued team member and is a highly-qualified professional. Ms. Spoon holds a Bachelor of Arts from National University in San Diego, California. In her personal time Ms. Spoon enjoys meditation, outdoor sports, and traveling.


The contents of this website: (i) do not constitute an offer of securities or a solicitation of an offer to buy securities, and (ii) may not be relied upon in making an investment decision related to any investment offering by Berg Capital Markets, LLC, or any affiliate, or partner thereof (“Berg”). Investment offerings and investment decisions may only be made on the basis of a confidential private placement memorandum issued by Berg Capital Markets, LLC, or one of its partner/issuers. Berg Capital Markets, LLC does not warrant the accuracy or completeness of the information contained herein.